NCT06866158View on ClinicalTrials.gov

Autologous Dendritic Cell as Adjunct Therapy for Diabetic Kidney Disease

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

August 5, 2024

Study Completion Date

August 5, 2025

Conditions
Diabetic Kidney Disease (DKD)
Interventions
BIOLOGICAL

Dendritic cell immunotherapy

DCL (Dendritic Cells+Lymphocytes) previously matured with S-Protein of SARS-CoV-2. The number of cells given depends on individual yields.

Trial Locations (1)

10410

Gatot Soebroto Central Army Hospital, Jakarta Pusat

All Listed Sponsors
collaborator

Rumah Sakit Pusat Angkatan Darat Gatot Soebroto

OTHER

collaborator

Universitas Prima Indonesia

UNKNOWN

collaborator

Universitas Pertahanan Indonesia

UNKNOWN

lead

PT. JES Kasih Nusantara Sejahterah

INDUSTRY